ijms-logo

Journal Browser

Journal Browser

Personalized Cancer Treatment: Harnessing the Power of Molecular Research

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 7218

Special Issue Editors


E-Mail Website
Guest Editor
Radiation Oncology Department, Hospital Universitario Ramón y Cajal, 28024 Madrid, Spain
Interests: prostate cancer; colorectal cancer; genitourinary cancers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Radiation Oncologist, National Clinical Director GenesisCare Spain, Vithas La Milagrosa and San Francisco de Asis Hospitals, 28002 Madrid, Spain
Interests: prostate cancer; radiation oncology; radiation therapy; radiation biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are living in an era of unprecedented development in cancer, both in the diagnosis of the disease with the introduction of advance imaging as well as with the implementation of molecular biomarkers which have diagnostic and prognostic implications that can allow us to personalize the treatment for our patients.

Molecular research is at the forefront of efforts to personalize cancer treatment. By comprehensively studying the molecular characteristics of tumors, identifying biomarkers, and designing targeted therapies, researchers are paving the way for more effective and precise cancer treatments. As molecular research continues to advance, personalized cancer treatment holds tremendous potential to improve patient outcomes and ultimately transform the landscape of cancer care.

This Special Issue aims to explore the molecular and/or therapeutic advances that already have a clinical use or that can transform the diagnostic and treatment paths of different tumors in the coming years. Please kindly note data on molecular mechanisms or pathophysiology are essential, and papers that only contain clinical trials/data are not acceptable.

Dr. Fernando López-Campos
Dr. Felipe Couñago
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • survival outcomes in oncologic setting
  • molecular biomarkers
  • advanced imaging
  • adaptive cancer treatment
  • precision cancer treatment
  • targeted therapies and Immunotherapy
  • personalized radiotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 578 KiB  
Review
Emerging Targets in Non-Small Cell Lung Cancer
by Louisa Liu, Joshua Soler, Karen L. Reckamp and Kamya Sankar
Int. J. Mol. Sci. 2024, 25(18), 10046; https://doi.org/10.3390/ijms251810046 - 18 Sep 2024
Cited by 8 | Viewed by 6730
Abstract
Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge [...] Read more.
Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in advanced NSCLC, elaborating on their clinical characteristics and specific mechanisms and molecular pathways for which targeted treatments are currently available. Additionally, we present an aggregate of ongoing clinical trials investigating the available treatment options targeting such alterations, in addition to their current recruitment status and preliminary efficacy data. These advancements may guide further research endeavors and inform future treatment strategies to improve the management of and transform outcomes for patients with advanced NSCLC. Full article
Show Figures

Figure 1

Back to TopTop